Search results
Results from the WOW.Com Content Network
It was announced in February 2006, that the UK government would introduce vaccination with the conjugate vaccine in children aged 2, 4 and 13 months. [24] [25] This included changes to the immunisation programme in general. [26] In 2009, the European Medicines Agency approved the use of a 10 valent pneumococcal conjugate vaccine for use in ...
The most common adverse reactions (reported in more than 10% of subjects vaccinated with pneumococcal polysaccharide vaccine in clinical trials) were: pain, soreness or tenderness at the site of injection (60.0%), injection-site swelling or temporary thickening or hardening of the skin (20.3%), headache (17.6%), injection-site redness (16.4%), weakness and fatigue (13.2%), and muscle pain (11.9%).
Streptokinase is a thrombolytic medication activating plasminogen by nonenzymatic mechanism. [1] As a medication it is used to break down clots in some cases of myocardial infarction (heart attack), pulmonary embolism, and arterial thromboembolism. [2]
For premium support please call: 800-290-4726 more ways to reach us
Group B streptococcal infection, also known as Group B streptococcal disease or just Group B strep infection, is the infectious disease caused by the bacterium Streptococcus agalactiae. Streptococcus agalactiae is the most common human pathogen belonging to group B of the Lancefield classification of streptococci —hence the name of group B ...
A study published in the British Medical Journal in 2013 looked at whether it could be applied to children aged 2–16. It was a retrospective study (2008–2010) and looked at 441 children who attended a Belgian hospital emergency department and had a throat swab taken. It concluded that the Centor criteria are ineffective in predicting the ...
Two children in the U.S. and 15 in the U.K. have died from strep A infection, a bacteria that normally causes mild disease but can be extremely dangerous.
Its use as a prophylactic treatment is supported by one clinical trial involving children with acute lymphoblastic leukaemia. [59] Other than this and one other clinical trial into its efficacy as a treatment for pneumocystis pneumonia, [ 60 ] data on its use in both the treatment and prevention of pneumocystis pneumonia is significantly lacking.